Add to ORKGIntroduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of high energy beta-particles. The development of watersoluble bone-seeking polymers such as PEI-MP (polyethyleneimine, functionalised with methylphosphonate-groups) that might be labeled with 188Re are recent approaches, with a strong potential for bone cancer treatment. The aim of this study was to evaluate the efficacy of 188Re-PEI-MP, as therapeutic agent for osteosarcoma, through in vitro and in vivo models
188Re is a beta- (Emax = 2.12 MeV) and gamma (155 keV) emitter. Since its chemistry is similar to th...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of hi...
Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of hig...
Introduction: The water-soluble polymer PEI-MP (polyethyleneimine, functionalised with methylphospho...
Introduction: The polymer PEI-MP (polyethyleneiminomethyl phosphonic acid) that might be labeled wit...
Introduction: The water-soluble polymer PEI-MP (polyethyleneimine, functionalised with methylphospho...
188Re is a beta and gamma emitter used in metabolic radiotherapy. SCINTIRAD is a multidisciplinary c...
International audienceRhenium-188 (Re-188) is a high energy beta-emitting radioisotope with a short ...
A b s t r a c t Designing ideal radiopharmaceuticals for use as bone pain palliatives require the us...
Resumo da comunicação apresentado ao XII Congresso Nacional de Medicina Nuclear, 12-14 Novembro 2009...
Abstract only availablePhosphonate ligands labeled with radioisotopes decaying by beta emissions hav...
Although established clinical utility is of key importance in choosing agents for radionuclide thera...
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis ...
188Re is a beta- (Emax = 2.12 MeV) and gamma (155 keV) emitter. Since its chemistry is similar to th...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...
Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of hi...
Introduction: 188Re is a promising radionuclide for metabolic therapy because of the emission of hig...
Introduction: The water-soluble polymer PEI-MP (polyethyleneimine, functionalised with methylphospho...
Introduction: The polymer PEI-MP (polyethyleneiminomethyl phosphonic acid) that might be labeled wit...
Introduction: The water-soluble polymer PEI-MP (polyethyleneimine, functionalised with methylphospho...
188Re is a beta and gamma emitter used in metabolic radiotherapy. SCINTIRAD is a multidisciplinary c...
International audienceRhenium-188 (Re-188) is a high energy beta-emitting radioisotope with a short ...
A b s t r a c t Designing ideal radiopharmaceuticals for use as bone pain palliatives require the us...
Resumo da comunicação apresentado ao XII Congresso Nacional de Medicina Nuclear, 12-14 Novembro 2009...
Abstract only availablePhosphonate ligands labeled with radioisotopes decaying by beta emissions hav...
Although established clinical utility is of key importance in choosing agents for radionuclide thera...
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis ...
188Re is a beta- (Emax = 2.12 MeV) and gamma (155 keV) emitter. Since its chemistry is similar to th...
Radionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less...
Hydroxyethylidene diphosphonate (HEDP) was prepared and labeled with rhenium-188. Its lyophilized ki...